KineMed uniquely employs both pathway-based drug discovery and translational medicine-enabled drug development.

KineMed's pathway-based discovery is based upon its unique ability to identify drugs with true therapeutic effect that effectively modulate the kinetics of key metabolic pathways. By screening compounds against these dynamic targets of key metabolic pathways that are the etiological basis for important diseases, KineMed can rapidly demonstrate a drug's on-mechanism activity in both animals and patients.

Translational medicine is the science of developing more predictive transitions from preclinical animal efficacy to human efficacy. With its proprietary ability to rapidly demonstrate whether a compound can effectively modulate the same metabolic pathway in both animals and man, KineMed is ideally positioned to de-risk the clinical development of new drug therapies. By measuring the real-time activity of drugs against their targeted metabolic pathways, KineMed can rapidly and easily identify therapeutic efficacy and dose response in First-in-Man studies.

KineMed works both with pharmaceutical companies and on its own developmental projects to speed new drugs to clinical use.

• In partnership with leading pharma companies or in our own development projects, we use these proven technologies to expedite the discovery of drugs that modulate biological pathways to mediate disease.
• For our lead programs, we are using both our pathway -based development technology to identify active drug candidates and our translational medicine capabilities to confirm the activity and dose-response in First-in-man studies.